Max Klement

Max Klement is currently a Principal at BioGeneration Ventures based in Amsterdam, North Holland, Netherlands. Prior to joining the firm in 2022, he served as an Investment Director at Life Sciences Partners and earned a PhD in Molecular Biology from the University of Amsterdam. He currently sources and manages early-stage biotech investments for a venture portfolio comprising more than 50 companies, recently leading a 2023 Series D financing round for Heartseed. His broader investment track record features direct involvement with clinical-stage entities like Argos Therapeutics, which was successfully acquired by Roche in 2018. Maintaining an active industry presence with over 5,000 professional network followers, he recently presented biotech funding trends at the BioEurope 2024 conference. Klement leverages his scientific background to bridge academic research and commercial healthcare, focusing primarily on emerging oncology, immunology, and platform technologies.